Prevent cancer preclinical drug development program - a novel multi-antigen vaccine (tnbcvax) to prevent triple negative breast cancer
Ended Awarded Last action
- Contract number
- 75N91021F00003
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,107,542
Award facts
- Contract value 100% obligated
- $1,107,541.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,985 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $631,014 | |
| Original award | $482,513 |
About this award
The National Cancer Institute awarded a $1.1 million firm fixed-price delivery order to the University of Oklahoma Health Sciences Center on September 16, 2021, for preclinical development of TNBCVax, a novel multi-antigen vaccine designed to prevent triple-negative breast cancer. This delivery order, which is scheduled for completion by November 15, 2025, operates under the PREVENT Cancer Preclinical Drug Development Program, a comprehensive National Cancer Institute initiative focused on evaluating the efficacy and pharmacodynamic biomarkers of potential cancer preventive agents. The work is being performed at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma, with no set-aside designation applied to this competitive award.
The University of Oklahoma Health Sciences Center has engaged Houston Methodist Hospital as a major subcontractor to conduct immunogenicity and anti-tumor efficacy studies of the TNBCVax vaccine in mouse models, including wild-type non-tumor-bearing mice and syngeneic tumor models derived from transgenic breast cancer cell lines. This preclinical research represents a critical phase in the drug development pipeline, establishing the scientific foundation necessary for advancing the vaccine candidate toward potential clinical applications. The institutional partnership leverages the University of Oklahoma's extensive federal research capabilities, demonstrated through substantial funding from the National Institutes of Health and National Cancer Institute, and Houston Methodist Hospital's established expertise in vaccine development and oncology research.
Quick answers
Who was awarded contract 75N91021F00003?
75N91021F00003 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 16, 2021.
How much is contract 75N91021F00003 worth?
The government has obligated $1,107,542 on 75N91021F00003.
Is contract 75N91021F00003 an order under another contract?
Yes. 75N91021F00003 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91021F00003 competed?
The extent of competition for 75N91021F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award